drugset

drugset / Trial / NCT00365300

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300 ↗

Phase 3 Completed 129 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).

Timeline

Start: 2006-09
Primary completion: 2007-11
Completion: 2007-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Pantoprazole	Other / unclassified	—	—

Indications